Search results for "JUVENILE IDIOPATHIC ARTHRITIS"

showing 10 items of 37 documents

Atypical presentation of anti-N-methyl-D-aspartate receptor encephalitis: two case reports

2017

Abstract Background Anti-N-methyl-D-aspartate receptor encephalitis is a rare autoimmune disease characterized by severe neurological and psychiatric symptoms and a difficult diagnosis. The disease is often secondary to a neoplastic lesion, seldom diagnosed years later. Psychiatric symptoms are prevalent in adults; neurologic symptoms are more evident in children, who typically present primarily with neurological symptoms. To the best of our knowledge, the association with juvenile idiopathic arthritis has not been described. Case presentation We report the cases of two caucasian girls with an atypical presentation. The first patient was an 8-year-old girl with normal psychomotor developmen…

PediatricsPathologyChoreiform movementAnti-Inflammatory AgentsArthritislcsh:MedicineCase ReportDisease0302 clinical medicinePrednisoneChildOvarian Neoplasms030219 obstetrics & reproductive medicineMedicine (all)Remission InductionTeratomaImmunoglobulins IntravenousGeneral MedicineMagnetic Resonance ImagingTreatment OutcomeMethylprednisoloneFemaleHip JointTeratomamedicine.symptomEncephalitismedicine.drugmedicine.medical_specialtyAdolescentAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Medicine (all)Methylprednisolone03 medical and health sciencesJuvenile idiopathic arthritiChoreaPsychiatric symptomsmedicineHumansImmunologic FactorsAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; TeratomaAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Adolescent; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Arthritis Infectious; Child; Female; Hip Joint; Humans; Immunoglobulins Intravenous; Immunologic Factors; Magnetic Resonance Imaging; Methylprednisolone; Ovarian Neoplasms; Remission Induction; Teratoma; Treatment Outcome; Medicine (all)Speech disorderSpeech disordersArthritis InfectiousPsychiatric symptombusiness.industrylcsh:RChoreaJuvenile idiopathic arthritismedicine.diseaseAnti-N-methyl-D-aspartate receptor encephalitisbusiness030217 neurology & neurosurgeryAnti-N-methyl-D-aspartate receptor encephaliti
researchProduct

Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease.

2019

Introduction: Only a few studies have reported the long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). We herein describe Anakinra (ANA) effectiveness expressed in terms of drug retention rate (DRR) and evaluate predictive factors of drug survival in sJIA and ASOD patients. Objectives: Examine the overall DRR of ANA in sJIA and AOSD patients. Explore the influence of biologic line of treatment, and the concomitant use of disease modifying anti-rheumatic drugs (cDMARDs) on DRR in the whole sample and stratified according to the disease thereafter; find eventual predictive factors associated with events l…

Settore MED/38 - Pediatria Generale E SpecialisticaAnakinraSettore MED/16 - REUMATOLOGIAAnakinra Systemic Juvenile Idiopathic Arthritis Still’s disease
researchProduct

Dermatologic adverse events associated with Juvenile Idiopathic Arthritis treatment

2020

Introduction: Steroids and disease-modifying anti-rheumatic drugs (DMARDs) are widely used in the treatment of juvenile idiopathic arthritis (JIA). Dermatologic adverse events including psoriasis have been reported in treatment of various inflammatory diseases (1-3). However, data regarding the occurrence of dermatologic adverse events in JIA patients are scarce (4-6). Objectives: To determine the prevalence of dermatologic adverse events in JIA patients treated with systemic steroids and DMARDs. To investigate an association between drugs and dermatologic adverse events and the association between anti-TNF treatment and psoriasiform lesions.

Settore MED/38 - Pediatria Generale E SpecialisticaDMARDs juvenile idiopathic arthritis Dermatologic adverse events
researchProduct

DEVELOPMENT AND INITIAL VALIDATION OF THE SYSTEMIC JADAS, A NEW COMPOSITE DISEASE ACTIVITY SCORE FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

2019

Background: Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile idiopathic arthritis (JIA). However, so far the JADAS has been validated only in children with the non-systemic categories of JIA. Objectives: To develop and validate the systemic JADAS (sJADAS), a new version of the JADAS specific to systemic JIA (sJIA). Methods: The sJADAS is made up by adding a fifth item, named Systemic Manifestation Score (SMS), to the four items included in the original tool (physician global assessment of disease activity, parent/patient global assessment of well-being, active joint count and ery…

Settore MED/38 - Pediatria Generale E SpecialisticaJADAS Juvenile Idiopathic Arthritis disease activity
researchProduct

EVALUATION OF THE DISEASE COURSE OF ITALIAN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH ETANERCEPT: PRELIMINARY RESULTS IN 1019 PATIENTS

2015

Methods: This is a multicenter, observational study that includes all children with JIA who were given ETN at Italian pediatric rheumatology centers after January 2000. Patients were classified in 2 groups: patients who were no longer taking ETN at study start (Group 1); patients who were still receiving ETN at study start (Group 2). Patients in Group 1 underwent only retrospective assessments, whereas patients in Group 2 underwent both retrospective and cross-sectional assessments. The primary outcome of the study were reasons for ETN discontinuation in patients in Group 1, and achievement of the states of inactive disease (ID), minimal disease activity (MDA) and parent- and child-acceptab…

Settore MED/38 - Pediatria Generale E SpecialisticaJUVENILE IDIOPATHIC ARTHRITIS ETANERCEPT JADAS
researchProduct

JUVENILE IDIOPATHIC ARTHRITIS AND FITNESS: A TEAMWORK

2018

Introduction: Patients with Juvenile Idiopathic Arthritis (JIA) have limited fitness and reduced aerobic and anaerobic exercise capacity vs. healthy peers. Furthermore, low intensity exercise programs are safe in children with JIA and may improve fitness, joint excursion and quality of life, reduce pain, fatigue and the employ to antiinflammatory drugs. Objectives: The purpose of the study was to evaluate postural and balance deficits and fitness with specific test battery in children and adolescents affected by JIA. Methods: We enrolled 30 patients with JIA (13 M; 17 F; age: 8-18 years); among those, 7 were evaluated longitudinally in the period 2016-2018, comparing the tests in different …

Settore MED/38 - Pediatria Generale E SpecialisticaJUVENILE IDIOPATHIC ARTHRITIS FITNESS
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: clinical inactive disease rate and safety in italian patients

2019

Introduction: Systemic juvenile idiopathic arthritis (sJIA) is a polygenic autoinflammatory disease. The pathophysiology is still unclear, it is now well known that innate immune mechanisms play a central role with overproduction of inflammatory cytokines. The increased knowledge on the role of these cytokines has provided a change in the natural history of the disease with the introduction of the targeted treatments. Remarkable results has been observed with canakinumab, an anti-interleukin-1β monoclonal antibody, in two clinical trials but little information are available in real life. Objectives: To evaluate clinical inactive disease rate and safety of canakinumab in Italian patients wit…

Settore MED/38 - Pediatria Generale E SpecialisticaSystemic juvenile idiopathic arthritis canakinumab IL1Canakinumab Systemic Juvenile Idiopathic Arthritis Interleukin-1β
researchProduct

Intra- and Juxta-Articular Osteoid Osteoma Mimicking Arthritis: Case Series and Literature Review

2023

Background: Intra- and juxta-articular osteoid osteomas are rare, representing less than 10% of all osteomas. Compared to the classic diaphyseal or metaphyseal site of long bones, they often have an atypical onset, a longest diagnostic delay, and frequent initial misdiagnoses, with pictures that can mimic inflammatory monoarthritis. We aimed to describe a case series, and to provide a literature review of this uncommon and misleading tumor location. Methods: We performed a retrospective analysis of patients referred to three pediatric rheumatology centers, with a final diagnosis of articular osteoid osteoma. A review of the literature was additionally conducted. Results: We included 10 pati…

Settore MED/38 - Pediatria Generale E Specialisticaarthritis bone tumor child diagnosis imaging joint pain juvenile idiopathic arthritis osteoid osteoma. rheumatic diseases synovitisPediatrics Perinatology and Child Healthosteoid osteoma; arthritis; child; joint pain; synovitis; juvenile idiopathic arthritis; rheumatic diseases; bone tumor; imaging; diagnosisChildren
researchProduct

Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etan…

2017

The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.

Settore MED/38 - Pediatria Generale E Specialisticabiologic medications etanerceptjuvenile idiopathic arthritis
researchProduct

Hypocomplementemia in children with juvenile idiopatic arthritis treated with tocilizumab: personal records

2017

The relieve of a reduction in complement levels was recently reported in adults with Rheumatoid Arthritis treated with tocilizumab (TCZ). However, there are no data in children with Juvenile Idiopathic Arthritis (JIA) treated with TCZ.

Settore MED/38 - Pediatria Generale E Specialisticatocilizumab Rheumatoid Arthritis Juvenile Idiopathic Arthritis
researchProduct